Lung cancer patients on drug from China’s Akeso lived longer

A lung cancer drug from China's Akeso, ivonescimab, extended patients' lives by about four months in a late-stage trial. Read ...

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results ...

Akeso, Inc. (9926.HK) (Akeso or the Company) today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meani ...